Daunorubicin/cytarabine
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Daunorubicin/cytarabine is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.[4][5] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.[4]
Quick Facts Combination of, Cytarabine ...
Combination of | |
---|---|
Daunorubicin | Anthracycline |
Cytarabine | Antimetabolite |
Clinical data | |
Trade names | Vyxeos |
Other names | CPX-351 |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Close